Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

The UCL–Lancet Commission on Migration and Health: the health of a world on the move


Executive Summary
With one billion people on the move or having moved in 2018, migration is a global reality. International migration has increased to 258 million, and the numbers of refugees and people displaced by conflict, natural disasters, and climate change are at their highest levels: 22 and 40 million, respectively. Despite negative political narratives, migration is not overwhelming high-income countries—instead, it takes place mostly between low-income and middle-income countries and most people are migrating for work. By and large, migration is a positive and diverse experience. But migration has also become a political lightning rod. 
The UCL–Lancet Commission on Migration and Health steps into this political debate to provide evidence for cooperation and action on what is one of the most pressing issues of the 21st century. The Commission’s foundation is that migration and health are inextricably linked—and key to sustainable development. It provides a framework of migration as a dynamic process, providing evidence of the multiple factors that could be beneficial or detrimental to individuals and systems along the migration journey—at origin, transit, destination, and return. It documents the devastating impacts of forced migration, especially on girls and women, but also the overall benefits to the health of individuals and populations that migration generates. It lays out a research agenda to better ensure the health of migrants. Using the lens of health the Commission shows that migration policies can be both ethical and feasible—calling for governments, international agencies, and professionals to promote health in global mobility.

Read More

Comments
Migration and health: human rights in the era of populism
Walid Ammar
The Lancet

"
Historically, the overall contribution of migrants to the economy and wealth of hosting countries has exceeded their costs. Migration helps address labour market imbalances, and migrants contribute more in taxes and social contributions than they receive in benefits. 
1 
However, increasing opposition to migration is expressed in political rhetoric and social media. Xenophobia and racism are galvanised by populist discourse that serves domestic political interests. A climate of intolerance facilitates the passing of discriminatory laws and the introduction of measures against migrants that contradict fundamental human rights. Additionally, public misinformation campaigns and the diffusion of fake news through social media make public opinion more receptive to extreme actions such as forced expulsions and building walls between peoples. The UCL– Lancet Commission on Migration and Health 
2 
makes a strong case for action to respond to the health needs of migrants while maximising the benefit from migration. The Commission provides evidence that discredits those who promote intolerance and shows that mortality is, on average, lower among migrants than people in host countries."

Link to the The Lancet Commission on Migration and Health
    ...
    166
    ...
ATC Name B/G Ingredients Dosage Form Price
J01MA14 QUINOMOX G Moxifloxacin (HCl) - 400mg 400mg Tablet, film coated 912,469 L.L
B01AF02 ELIQUIS B Apixaban - 5mg 5mg Tablet, film coated 4,183,603 L.L
C09CA03 VIOSTAN 320 G Valsartan - 320mg 320mg Tablet, film coated 1,338,467 L.L
C10AA05 TORVALIP 40 G Atorvastatin (calcium) - 40mg 40mg Tablet, film coated 1,164,664 L.L
G04BX14 PRILIGY B Dapoxetine (hydrochloride) - 30mg 30mg Tablet, film coated 1,957,979 L.L
J01MA14 AVITAR 400 G Moxifloxacin (HCl) - 400mg 400mg Tablet, film coated 913,813 L.L
N06DA02 DOPEZIL G Donepezil HCl - 5mg 5mg Tablet, film coated 1,034,759 L.L
C09CA03 VIOSTAN 40 G Valsartan - 40mg 40mg Tablet, film coated 526,786 L.L
C10AA05 TARDELIP G Atorvastatin - 40mg 40mg Tablet, film coated 1,055,876 L.L
G04BX14 LEJAM G Dapoxetine (hydrochloride) - 30mg 30mg Tablet, film coated 1,269,931 L.L
J01MA14 AVITAR 400 G Moxifloxacin (HCl) - 400mg 400mg Tablet, film coated 651,764 L.L
B01AF02 AVIXAN G Apixaban - 5mg 5mg Tablet, film coated 2,777,275 L.L
C09CA04 APROVEL B Irbesartan - 150mg 150mg Tablet, film coated 651,764 L.L
G04BX14 PRIXETIN 30 G Dapoxetine (hydrochloride) - 30mg 30mg Tablet, film coated 2,105,353 L.L
N06DA02 DONECEPT 5 G Donepezil HCl - 5mg 5mg Tablet, film coated 1,970,969 L.L
R03DC03 SINGULAIR B Montelukast (sodium) - 10mg 10mg Tablet, film coated 1,248,430 L.L
B01AF02 ELIQUIS B Apixaban - 2.5mg 2.5mg Tablet, film coated 4,183,603 L.L
C09CA04 APROVEL B Irbesartan - 150mg 150mg Tablet, film coated 651,764 L.L
G04BX14 PRILIGY B Dapoxetine (hydrochloride) - 60mg 60mg Tablet, film coated 1,957,979 L.L
J01MA14 FLOXIMOX G Moxifloxacin (HCl) - 400mg 400mg Tablet, film coated 1,062,276 L.L
N06DA02 ARIPEZIL 5 G Donepezil HCl - 5mg 5mg Tablet, film coated 1,970,969 L.L
R03DC03 ROMILAST G Montelukast (sodium) - 10mg 10mg Tablet, film coated 228,453 L.L
C09CA04 GIZLAN G Irbesartan - 150mg 150mg Tablet, film coated 748,520 L.L
C10AA05 TARDELIP G Atorvastatin - 80mg 80mg Tablet, film coated 1,055,876 L.L
G04BX14 PRIXETIN 60 G Dapoxetine (hydrochloride) - 60mg Tablet, film coated 1,479,123 L.L
N06DA02 ARICEPT B Donepezil HCl - 10mg 10mg Tablet, film coated 3,776,197 L.L
R03DC03 LUKAST G Montelukast (sodium) - 10mg 10mg Tablet, film coated 802,274 L.L
B01AF02 AVIXAN G Apixaban - 2.5mg 2.5mg Tablet, film coated 2,777,275 L.L
C10AA07 CRESTOR B Rosuvastatin (calcium) - 10mg 10mg Tablet, film coated 804,962 L.L
N06DA02 DONEPEZIL ARROW G Donepezil HCl - 10mg 10mg Tablet, film coated 1,365,344 L.L
    ...
    166
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025